Technology

The depth and breadth of our capabilities is what sets us apart. Our proprietary vectored and synthetic platform technologies are based on decades of research at leading institutions (NIH, University of Oxford) and have been optimized to meet the demands of different therapeutic applications.

For each therapeutic area we draw upon a broad toolbox of platform technologies for systematically engineering product candidates that aim to overcome disease and address patient needs. This is achieved through the modularity of our platforms which can be uniquely tailored to guide T cell responses, with a focus on two main approaches:

• Reducing inflammation to treat autoimmunity and other inflammatory diseases.
• Eliminating virally infected or cancerous cells to treat chronic infectious diseases and cancer.

Our proprietary SNAP (Self-assembling Nanoparticles based on Amphiphilic Peptides) platform was developed to address the need for co-delivering multiple active pharmaceutical ingredients in nanoparticles. This fully synthetic, biocompatible platform utilizes self-assembly to co-deliver multiple antigens and immunomodulators. This approach allows for nanoparticles of a precise, programmable size and composition for inducing the specific T cell populations needed for diverse therapeutic indications.

The SNAP platform optimized for promoting tolerance for treating autoimmunity and other inflammatory diseases is referred to as SNAP Tolerance Immunotherapy, abbreviated as “SNAP-TI.”

Barinthus Bio has deep capabilities and expertise in the design and optimization of vectored and nucleic acid-based platforms. Our most advanced vectored platforms are ChAdOx1 (Chimpanzee Adenovirus Oxford), which is a modified, replication-incompetent simian adenoviral vector, and Modified Vaccinia Ankara (MVA), a well-studied attenuated vaccinia virus.

Our vectored platforms are optimized for promoting highly disease (antigen)-specific T cells against target antigens encoded by the vectors. For treatment of chronic infectious diseases and cancer, we have optimized an approach whereby ChAdOx and MVA are given sequentially to maximize T cell immunity. This differentiated approach reproducibly achieves high magnitude, quality, and durability of antigen-specific CD4 helper and CD8 cytotoxic T cells ideal for treating infectious diseases and cancer.